Reduced expression of BRCA1 has been reported in sporadic breast cancer, although the mechanisms underlying this phenomenon remain unclear. Abnormal methylation leading to silencing of tumour suppressor genes has been implicated in tumorigenesis in a wide range of sporadic cancers. Therefore, we sought to determine the frequency of methylation within the BRCA1 promoter region in a large group of sporadic invasive breast (n=96) and ovarian (n=43) carcinomas using Southern analyses. Overall, methylation was detected in 11% of breast cancer cases and in 5% of ovarian tumours. Methylation of the BRCA1 promoter region was strongly correlated with lack of estrogen and progesterone receptor expression. It is clear from the frequency of abnormal methylation of the BRCA1 promoter region, that this cannot be the sole mechanism mediating the reduced expression of BRCA1 that has previously been reported to occur in the majority of invasive sporadic breast tumours. Nevertheless this study suggests that abnormal methylation of the BRCA1 promoter may be important in tumorigenesis in a subset of sporadic breast and ovarian cancers.
Introduction
Since the breast cancer susceptibility gene BRCA1 was isolated , more than 300 disruptive germline mutations within the coding region of the gene have been identi®ed in cases of familial breast and ovarian cancer (Couch et al., 1996) . Several observations strongly support a role for BRCA1 as a tumour suppressor gene: growth of normal and malignant mammary cells is accelerated upon experimental inhibition of BRCA1 expression with antisense oligonucleotides (Thompson et al., 1995) , whilst overexpression of wild-type BRCA1 inhibits malignant breast and ovarian cancer cell growth in culture and suppresses MCF-7 breast cancer cell tumorigenesis in mice (Holt et al., 1996) . Furthermore, the degree of loss of heterozygosity at the BRCA1 locus is high in sporadic breast and ovarian cancer (Cropp et al., 1993; Saito et al., 1993; Ford et al., 1994) . In contrast to other tumour suppressor genes, no somatic mutations of BRCA1 have been found in sporadic breast cancer, which accounts for about 90% of cases. Furthermore, somatic mutations have only rarely been detected in ovarian cancers Hosking et al., 1995; Merajver et al., 1995) . However, it has been shown that BRCA1 mRNA levels are reduced or absent in breast cancer cell lines and sporadic breast carcinomas (Thompson et al., 1995; Sourvinos and Spandinos, 1998) , thereby implicating BRCA1 in sporadic as well as familial disease. The mechanisms underlying this reduced expression of BRCA1 are unclear.
In an attempt to determine the regulation of the BRCA1 gene as well as to understand the normal function of the gene product, we have previously examined the promoter region in detail and demonstrated its complex regulation. The BRCA1 gene has two promoters (a and b), controlling the expression of two distinct transcripts a and b (where exon 1A and 1B are the ®rst exons respectively); the a promoter is shared with the adjacent NBR2 gene and is bidirectional (Xu et al., , 1997 Brown et al., 1996) . We showed in a recent study that mutations within these BRCA1 promoter regions are unlikely to account for the reduction of BRCA1 levels reported in sporadic breast tumours (Catteau et al., in press ). This suggests that alternative mechanisms such as DNA hypermethylation, dysregulation of transcriptional activators and/or repressors binding to the BRCA1 locus or post-transcriptional processes could be involved.
A role for abnormal methylation in carcinogenesis has already been established in other tumours, either through generation of oncogenic point mutations at CpG dinucleotides, or through epigenetic silencing of tumour suppressor genes. Hypermethylation of a tumour suppressor gene was ®rst described for the RB gene in sporadic cases of retinoblastoma (Sakai et al., 1991; Ohtani-Fujita et al., 1993; Greger et al., 1994) . Similarly, hypermethylation has been described for other tumour suppressor genes such as the VHL (von Hippel-Lindau) gene in spontaneous renal carcinoma (Herman et al., 1994) , the p15 gene in primary gliomas and leukemias (Herman et al., 1996) , the p16 gene in a large variety of primary tumours Merlo et al., 1995) and the APC (Adenomatous Polyposis Coli) gene in colorectal carcinoma (Hiltunen et al., 1997) .
Recently it has been shown that methylation within the promoter region of BRCA1 occurs in some cases of sporadic breast cancer (Dobrovic and Simpfendorfer, 1997; Mancini et al., 1998) . In the present study, we sought to determine by analysis of a large number of sporadic breast and ovarian carcinomas the frequency of this phenomenon and also to analyse the relationship between methylation status and the clinicopathological parameters of the disease.
Results
A CpG island is present at the 5' end of the BRCA1 gene, encompassing more than 2000 nucleotides . This region includes the ®rst exon of NBR2 and its bidirectional a promoter, together with the b promoter (Xu et al., 1997) and exons 1A and 1B of BRCA1. The methylation status of the 5' region of BRCA1 was examined by Southern analysis. We used the methylation-sensitive restriction enzyme SmaI cutting within fragments generated by the methylation insensitive enzyme PstI. As the BRCA1 genomic region is tandemly duplicated, with a pseudo-copy of BRCA1 exons 1 and 2 lying head to head with the NBR1 gene (Barker et al., 1996; Brown et al., 1996) , (accession no. U72483), the 1.3 kb probe used detects fragments in both regions (Figure 1 ). Single digestion of DNA with PstI produces three fragments: a 3798 bp fragment corresponds to the p3ba sequence (accession no. U37574) (Xu et al., 1997) including the ®rst three exons of the BRCA1 gene (1A, 1B, and 2), and the ®rst exon of NBR2; the two other fragments (6.5 and 2.6 kb) are generated from the duplicated region (Figures 1 and 2a) . When all the SmaI sites present in these PstI fragments are unmethylated, combined digestion with SmaI would be expected to yield ®ve fragments. Two of them, a 1681 bp fragment (nucleotides position 33 ± 1714) and a 409 bp fragment (nucleotides position 1714 ± 2123) are derived from the BRCA1 promoter region; the three other fragments of 1260 bp (nucleotides position 264 ± 1524), 284 bp (nucleotides position 1524 ± 1808) and 136 bp (nucleotides position 1808 ± 1944) are derived from the pseudo-BRCA1 promoter region (Figures 1 and 2b , lane 1). Figure 1 Schematic representation of the 5' region of BRCA1 with the corresponding pseudocopy, showing the position of the probe used to determine the methylation status of the BRCA1 promoter region (not shown to scale). The top diagram shows the 3798-bp PstI fragment corresponding to the p3ba sequence (accession no. U37574). The solid boxes represent the BRCA1 exon 1A, exon 1B and exon 2. The hatched box indicates the NBR2 ®rst exon, a and b refer to the two BRCA1 promoters. The enlarged section indicates the distribution of the individual CpGs sites in relation to the SmaI and transcription factor binding sites (dashes). The lower diagram shows the duplicated region (Barker et al., 1996; Brown et al., 1996) (accession no. U72483). The dark grey boxes represent the pseudo-BRCA1 exon 1A, exon 1B and exon 2; the open boxes denote partial pseudo-ARPP1 sequence inserted upstream of exon 1A and an Alu element in exon 1B (Barker et al., 1996; Brown et al., 1996) ; the light grey boxes represent the NBR1 exon 1A and exon 1B. The arrows indicate the direction of transcription for the dierent genes. The heavy black lines (A and B) indicate the region of homology between the probe used (nucleotide position 608 ± 1926, accession no. U37574) and the respective genomic sequence. The position of the restriction sites are indicated (P = PstI; S = SmaI; *downstream SmaI site). The size of fragments detected by the probe, when there is no methylation at the SmaI sites are shown beneath each sequence Frequency of BRCA1 promoter methylation in sporadic breast and ovarian cancer Based on the Southern analysis described above, we have examined the DNA methylation status of the regulatory region of BRCA1 in a large series of sporadic breast and ovarian tumour samples (n=96 and n=43 respectively) and in breast (n=5) and ovarian cancer (n=1) cell lines. In 15 cases of sporadic breast cancer, peripheral blood DNA was also studied. In addition, we analysed a cell line derived from normal breast tissue, two normal breast tissue samples, and chorio-placenta and lymphoid cell lines. The disease characteristics relating to the clinical material studied are presented in Tables 1 and 2 , the breast and ovarian cancer cell lines are described in the Materials and methods section. As expected for an autosomal gene, the pattern of fragments obtained from all the peripheral blood specimens, the non-neoplastic breast samples and cell line and also from the chorio-placenta and lymphoid cell lines was consistent with lack of methylation at the SmaI sites (e.g. Figure 2b , lane 1). The same pattern was observed for the breast and ovarian cancer cell lines and for the majority of the sporadic breast and ovarian tumours (see Figure 2b , lanes 3 and 4). However, in 13 cases (11 sporadic breast tumours and two sporadic ovarian tumours) additional larger fragments were observed indicating methylation in the BRCA1 promoter region. It was con®rmed that this did not re¯ect an artifact due to incomplete digestion by: (1) observation of the expected bands from the duplicated region; and (2) by control digestion of the same samples with the restriction enzyme XmaI, the methylation-insensitive isoschizomer of SmaI (Figure 2b , lanes 9 and 11).
In 5/13 cases (Table 1, sample nos. 848, 855, 1073, 1094, 1207) , an additional 3765 bp fragment was detected, indicating methylation at both SmaI sites in the BRCA1 promoter region (Figures 1 and 2b , lanes 2 and 5). In 2/13 cases (one breast tumour ± Table 1 , sample no 6 and one ovarian tumour ± Table 2 , sample no. 17), a 2090 bp fragment was detected, resulting from methylation only at the downstream SmaI site (Figures 1 and 2b , lane 10). In the remaining six cases both additional fragments (3765 bp and 2090 bp) were detected. Figure 2b , lanes 6 ± 8). Amongst the whole group of cases with methylation within the BRCA1 promoter region, fragments of 1681 bp and 409 bp were invariably detected indicating the coexistence of unmethylated DNA; it was also noted that the relative intensity of each of the additional bands varied both within and between cases ( Figure 2b , compare lanes 5 ± 8 and 10). These observations could be accounted for by the presence of residual normal breast tissue, by an allelic eect whereby methylation within tumour cells does not invariably aect both alleles, and also by inter-and intra-tumour heterogeneity in the methylation pattern.
Relationship between BRCA1 promoter methylation and disease characteristics
We also explored the relationship between the methylation status of the regulatory region of BRCA1 Figure 2 Analysis of the methylation status within the promoter region of BRCA1 by Southern analyses. All the blots were hybridized with the 1.3 kb BRCA1 probe described in Figure 1 . (A) Single PstI digestion of lymphocyte DNA. The heavy arrow indicates the 3.8 kb (3798 bp) fragment derived from the BRCA1 promoter region, the two thin arrows indicate the sizes of the fragments from the duplicated region. (B) Double digestion with PstI and SmaI (lanes 1 ± 8 and 10). Lane 1: Demonstrates the pattern of fragments observed in the absence of methylation at either SmaI site in the BRCA1 promoter region and corresponding pseudocopy, shown here is an example from normal breast tissue. Heavy arrows refer to fragments derived from the BRCA1 promoter region and thin arrows are derived from the pseudocopy (see Figure 1 ). An identical pattern was observed in MCF-7 breast cancer cell line (lane 3) and also in a series of 85 sporadic breast tumours and 41 sporadic ovarian tumours, an example of an unmethylated breast tumour case is shown in lane 4. Lanes 2 and 5: Invasive sporadic breast carcinomas; in these lanes the presence of an additional 3765 bp fragment is seen indicating methylation of both SmaI sites in the BRCA1 promoter region. Lane 10: Demonstrates the presence of an additional 2090 bp fragment indicating methylation solely at the downstream SmaI site of the BRCA1 promoter region; an example of a sporadic breast tumour is shown here. Lanes 6 ± 8: In these lanes both additional fragments are observed, lane 6 ovarian tumour, lanes 7 and 8 are breast tumours. Lanes 9 and 11: Control double digestion using PstI and XmaI from DNA samples previously digested with PstI and SmaI shown in lanes 8 and 10 respectively Table 4 ). Of the 11 cases showing methylation, 10 were ER7 and all 11 were PR7. When the two receptors were considered together, all of the 40 ER+/PR+ breast tumours examined were devoid of methylation at both SmaI sites analysed, whereas 24% (10/41) of the ER7/PR7 breast tumours were methylated. Therefore, virtually all the methylated tumours were ER7/PR7 (10/11, 91%). The remaining methylated case was ER+/PR7 and was noted to be the only tumour in which methylation was detected solely at the downstream SmaI site (Table 1 , sample no. 6; Figure 2b , lane 10).
Discussion
A potential role for BRCA1 in sporadic tumorigenesis has been inferred from LOH studies which showed that the BRCA1 region is frequently lost in breast (Cropp et al., 1993; Saito et al., 1993; Ford et al., 1994) and ovarian tumours (Russell et al., 1990; Cliby et al., 1993; Yang-Feng et al., 1993; Takahashi et al., 1995) . Unlike other tumour suppressor genes however, few somatic mutations have been found in sporadic ovarian cancer and none identi®ed in sporadic breast cancer. Nevertheless, the demonstration of reduced levels of BRCA1 mRNA in sporadic breast tumours suggests that BRCA1 may be involved in both forms of the disease (Thompson et al., 1995; Sourvinos and Spandinos, 1998) . The decreased expression could be explained by the presence of mutations in the promoter region of BRCA1; however, recently we showed that such mutations must be an uncommon event in sporadic breast tumours if indeed they occur at all (Catteau et al., in press ). Here we have investigated the methylation status of the promoter region of the BRCA1 gene, an epigenetic mechanism which has been shown to be an alternative pathway for the inactivation of tumour suppressor genes (Laird and Jaenisch, 1996) . It is clear that a number of speci®c loci are hypermethylated in breast tumours or cell lines. These include the 5' CpG islands of genes encoding calcitonin (Hakkarainen et al., 1996) , p16 , estrogen and progesterone receptors (Ottaviano et al., 1994; Ferguson et al., 1995; Lapidus et al., 1996) and E-cadherin (Gra et al., 1995) . Methylation-sensitive restriction ®ngerprinting has identi®ed two further hypermethylated loci, HBC-1 and HBC-2 associated with breast cancer (Huang et al., 1997) . More recently, hypermethylation has also been observed in the promoter region of BRCA1 in cases of sporadic breast and ovarian cancer. Using Southern analysis Dobrovic and Simpfendorfer (1997) , detected two methylated cases amongst seven sporadic breast carcinomas, whilst Mancini et al. (1998) identi®ed methylation in 2/6 breast tumours and in 2/5 ovarian tumours employing the sodium bisul®te protocol.
The present study con®rms these ®ndings; we have shown that the promoter region of the BRCA1 gene is d,e criteria for receptor status are de®ned in Materials and methods. un.=unknown. *paired peripheral blood samples were available for these patients, and in each case the BRCA1 promoter region was found unmethylated hypermethylated in a subset of breast sporadic tumours (11%, 11/96) and in a few sporadic ovarian tumours (5%, 2/43). No aberrant methylation was observed in normal breast tissue, in various normal cell lines (breast, ovarian, placenta, lymphoid) or indeed in mononuclear cells derived from the peripheral blood of breast cancer patients, including those in whom tumour DNA was methylated. This would suggest that abnormal methylation of BRCA1 is tumour speci®c, which is consistent with previous studies (Dobrovic and Simpfendorfer, 1997; Mancini et al., 1998) . Hypermethylation of the BRCA1 promoter could silence gene expression, as has previously been demonstrated for other tumour suppressor genes. This phenomenon could account for the fact that loss of heterozygosity (LOH) in the BRCA1 region in sporadic breast cancer, and in the majority of sporadic ovarian cancers, is not linked to mutation of the remaining allele. Moreover, LOH has not been detected in all tumours and it would be of interest to determine whether methylation accounts for gene silencing of BRCA1 in some of these cases. One potential mechanism by which methylation could abrogate gene expression is by impairing the interaction of transcription factors with DNA binding sites. In this regard the putative CREB binding motif (Xu et al., 1997) present in the a promoter of BRCA1 has been found to be methylation sensitive (Mancini et al., 1998) . We have previously characterised other putative transcription factor binding sites within the BRCA1 promoter region (Xu et al., 1997) and have established that the 5' SmaI site analysed here lies in close proximity to an Sp1 binding motif (Figure 1) . Conversely, it has also been suggested that the Sp1 elements play a key role in protecting CpG islands from de novo methylation (Brandeis et al., 1994; Macleod et al., 1994) . In view of this we were interested to determine whether BRCA1 promoter methylation was associated with mutations within the adjacent Sp1 site; however no such mutations were found amongst six methylated breast cancer cases (Catteau et al., in press ).
Our results also suggest that there is heterogeneity in methylation patterns both within and between tumours (Figure 2b ). This issue has been addressed by the use of the sodium bisul®te protocol which permits the determination of the methylation status of distinct subclones within the tumour (Mancini et al., 1998) . This technique indeed revealed heterogeneity both at particular CpG sites and between individual clones. As proposed by the authors, this heterogeneity may be accounted for by the presence of normal stromal cells, sampling of cells at various stages of progression towards tumorigenesis or of populations of tumour cells subject to clonal evolution. In addition the methylation mosaicism could result from allele-specific methylation. This heterogeneity in methylation patterns is reminiscent of the variability observed in the reduced expression of BRCA1 between dierent sporadic breast tumours (Thompson et al., 1995; Sourvinos and Spandinos, 1998) . BRCA1 mRNA levels have been shown to be up to 15-fold higher in normal mammary tissue than in invasive tumour material.
In the present study we observed methylation of the BRCA1promoter region in 11% of sporadic breast tumours and in 5% of sporadic ovarian cases. Whilst the technique employed may have underestimated the true incidence of methylation, it should be noted that other studies, including one which used the sodium bisul®te protocol, similarly did not detect methylation in all sporadic cases (Dobrovic and Simpfendorfer, 1997; Mancini et al., 1998) . On this basis it appears unlikely that methylation can account for the reduction in BRCA1 levels observed in the majority of sporadic breast tumours, suggesting that alternative mechanisms are involved. This is supported by analyses in the MCF-7 cell line which has been demonstrated to have reduced levels of BRCA1 mRNA relative to normal mammary cells (Thompson et al., 1995) , in the presence of a normal methylation pattern in all regions of the BRCA1 promoter examined to date in this (Figure 2b , lane 3) and previous studies (Dobrovic and Simpfendorfer, 1997; Mancini et al., 1998) .
The advantage of our study is that it aords the opportunity to determine whether abnormal methylation at the CpG sites analysed was correlated with disease characteristics in a relatively large group of sporadic breast cancer cases. No correlation was observed with age, menopausal status, or tumour grade or stage; however there was a strong correlation with the estrogen and progesterone receptor status. Approximately 70% of in®ltrating mammary carcinomas are ER+ and approximately 50% are PR+. When the two receptors are considered together, 50% of tumours are double positive (ER+/PR+), 25% are double negative (ER7/PR7) (Barnes and Millis, 1995) . We observed that none of the ER+/PR+ tumours were methylated, whilst 10/11 of the methylated breast tumours had a ER7/PR7 phenotype. As ER is required as a transcriptional activator for the expression of PR (Read et al., 1988) , it is not surprising that a correlation found with one of the receptors is associated with a correlation with the other. Interestingly the two methylated cases reported by Dobrovic and Simpfendorfer (1997) for which dierent CpG sites were analysed, were both ER7, whilst the ®ve unmethylated tumours were ER+. Lack of expression of ER in breast tumours has itself previously been shown to be correlated with methylation at the 5' CpG island of the gene; a similar correlation has been established for PR (Ferguson et al., 1995; Lapidus et al., 1996) . It is striking that the ER CpG island has been found to be hypermethylated in 25% of ER7 breast cancers (Lapidus et al., 1996) , i.e. the same proportion of ER7 cases found to be hypermethylated in the BRCA1 promoter region in the present study. We are currently seeking to determine whether they do indeed represent the same population. This will be of particular interest as a recent study has suggested that reduced expression of BRCA1 in sporadic breast cancer is correlated with negative ER status (Sourvinos and Spandinos, 1998) . It has also been noted that there is an increase in DNA methyltransferase activity in ER7 cell lines compared to ER+ lines, leading to the suggestion that lack of expression of ER in these cells was mediated by increased methylation (Ottaviano et al., 1994) . This raises the possibility that abnormal methylation of the BRCA1 promoter in ER7 tumours may also be secondary to increased DNA methyltransferase activity.
In conclusion, our study based on the analysis of a large series of breast and ovarian cancers con®rms that BRCA1, in common with other tumour suppressor genes, is abnormally methylated in sporadic tumours. Interestingly, the frequency of this phenomenon was comparable to that described for other genes in other solid tumours (Greger et al., 1994; Herman et al., 1994; Sakai et al., 1991) and therefore implies that methylation of BRCA1 could play a key role in breast and ovarian tumorigenesis. As abnormal methylation was detected in approximately a tenth of sporadic breast tumours, it indicates that this mechanism alone cannot account for the reduction in BRCA1 mRNA levels observed in the majority of sporadic invasive breast cancer cases (Thompson et al., 1995) . Nevertheless, the correlation between methylation of the BRCA1 promoter region with ER and PR expression raises the possibility that abnormal methylation could be a more generalized phenomenon in a subset of breast carcinomas.
Materials and methods

DNA samples
To study the methylation status of the BRCA1 regulatory region, a large series of DNA samples (n=165) derived from dierent sources were analysed. DNA was extracted using a chloroform high salt precipitation method adapted from Blin and Staord (1976) .
Sporadic breast and ovarian tumours DNA was extracted from 96 samples of sporadic in®ltrating mammary carcinoma obtained from patients treated in the Imperial Cancer Research Fund Clinical Unit at Guy's Hospital (London, UK) and from 43 samples of sporadic ovarian adenocarcinoma taken from patients treated in the Department of Obstetrics and Gynaecology at St Thomas' Hospital, (London, UK). None of these patients had a family history of breast or ovarian cancer. The mean age at diagnosis of the breast cancer patients was 51 years (29 ± 81); 48 patients were pre-menopausal, eight perimenopausal and 37 were post-menopausal (data missing for three patients). The mean age at diagnosis of the ovarian cancer patients was 59 years (33 ± 80). In two sporadic breast cancer patients, DNA was also collected from normal breast tissue, whilst in a further 15 patients matched lymphocyte DNA was extracted.
Cell lines DNA was extracted from a variety of cell lines: ®ve breast cancer cell lines: MCF-7, T47D, ZR-75 (ER positive); MDA-MB-231 and MDA-MB-468 (ER negative); MTSV1-7 which was derived from normal breast epithelial cells immortalized with a temperature sensitive SV40 large T antigen; an ovarian carcinoma cell line, SKOV-3; a normal chorio-placenta cell line, JAR and the T-lymphoid cell-line Molt4.
Estrogen Receptor (ER) status of breast carcinomas was determined by one of the following techniques: (i) cytosol immunoassay (E1A) using antibody H222, as supplied in the ER-EIA kit from Abbott Laboratories (North Chicago II, USA). The method was carried out according to the manufacturer's instructions. A cut-o point of 20 fmol mg 71 of cytosol protein was used to dierentiate between positive (ER+) and negative (ER7) ER status; (ii) immunohistochemical assay using ER ID5 monoclonal antibody (DAKO Ltd, Ely, Cambridge, UK) in a peroxidase conjugated streptavidin-biotin technique (Barnes et al., 1996) . Carcinomas were considered as ER positive when more than 20% of the tumour cells stained positively. Progesterone receptor (PR) status was assessed either by EIA using antibody Abbott KD68 with the Abbott PR-EIA kit according to the manufacturer's instructions. Immunohistochemical staining was carried out using the NCLPGR antibody, also with a peroxidase conjugated streptavidin biotin technique. PR staining was evaluated in the same way as ER. The use of two dierent methods of receptor assay re¯ects a change in practice in the breast pathology laboratory during the time that the tumour samples were collected. The two methods have been shown to give comparable results (Barnes et al., 1996) .
Southern blots
Five mg of DNA was digested initially with 100 units of PstI for 16 h under appropriate conditions speci®ed by the supplier (New England Biolabs). DNA was then digested with an excess of the methylation sensitive enzyme SmaI (80 units) or with its methylation-insensitive isoschizomer XmaI, both under conditions speci®ed by supplier (Pharmacia). Digested DNA was separated by electrophoresis through an 0.8% agarose gel and transferred to Hybond N + membranes (Amersham) for subsequent hybridization. The BRCA1 promoter region probe was generated using an 1.3 kb PCR product from cosmid A11100 (Brown et al., 1996) . Hybridization was carried out overnight at 658C, followed by washes at room temperature with 16SSC-0.1% SDS and a ®nal wash at 658C with 0.56SSC-0.1% SDS.
